Neuroblastoma
Conditions
Keywords
Adrenal Gland, No stage requirement
Brief summary
The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and tumor growth in test tubes. Your blood, marrow, and hematopoietic stem cell samples will also be tested for tumors or leukemia cells, and your serum tested for anti-tumor antibodies.
Detailed description
To collect tumor, marrow specimens prospectively to study the molecular-genetic makeup of individual neuroblastic tumor and its metastasis by blood and marrow, and to correlate these findings with clinical outcome, and to relate the signaling circuitry of neuroblastic tumors to that of embryonic neuroectodermal cells. .
Interventions
OTHERTumor and Marrow Markers
Tumor and Marrow Markers
Sponsors
Southern Illinois University
Spanish National Cancer Center
St. Jude Children's Research Hospital
Washington University School of Medicine
University of Texas
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Neuroblastic tumors diagnosed in accordance with the International Neuroblastoma Staging System OR * Clinically suspected neuroblastic tumors. PK DRAW INCLUSION CRITERIA (FOR PK DRAWS ONLY): PK Draw Inclusion Criteria * Patients who receive naxitamab as part of their standard of care
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To study the molecular-genetic makeup and metastasis of neuroblastic tumors. | 2 years | Before surgery a maximum of 5 blood drawings (20-30 ml) will be performed per year (at least one month apart) per patient |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To study the correlation of these biologic markers with clinical outcome. | 2 years | Before surgery and a maximum of 5 blood drawings (20-30 ml) will be performed per year (at least one month apart) per patient |
| To relate neuroblastic tumor and embryonic neuroectodermal cell circuitry. | 2 years | Up to six fetal adrenal samples will be obtained (without patient identifiers) from gestational week 20, when neuroblasts are present and thought to be differentiating within the fetal adrenal gland. |
Countries
United States
Contacts
Primary ContactNai-Kong Cheung, M.D., Ph.D.
Backup ContactShakeel Modak, MD
Outcome results
None listed